Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Captions are provided by our contributors
Improvement in liver fibrosis was observed in 34% of the 6.0 mg group compared with 22% in the placebo group
Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics
Liverrelated outcomes in EPP (observational) A retrospective cohort (n=70) found afamelanotide exposure associated with dosedependent improvements in liverfunction tests (decreased ALAT and bilirubin with more doses in the prior year) and lower PPIX when more recently dosed
The coverage varies by program and state
Among those planning to skip a dose, 51% say their physician advised against it, while 29% say their doctor said it was acceptable
